At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 577 enrolled
Drug / intervention
Dulaglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
In Brief
A Phase 3 clinical trial evaluating Dulaglutide, Insulin glargine, and 1 other intervention for Type 2 Diabetes and Chronic Kidney Disease. Completed, enrolled 577 participants across 89 sites in 9 countries.
Detailed Summary
The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Chronic Kidney Disease
CountriesBrazil, Hungary, Mexico, Poland, Romania, South Africa, Spain, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartJul 2012
Primary CompletionJun 2016
Study CompletionDec 2016
TodayJul 2026
First PostedJun 18, 2012
Enrollment StartJul 1, 2012
Primary CompletionJun 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 14.0 years ago
Interventions
Dulaglutidedrug
Administered SC
Insulin glarginedrug
Administered SC
Insulin lisprodrug
Administered SC